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The burden of allergic diseases in the Indian subcontinent: 
barriers and challenges
Allergic diseases occur because of a complex interplay 
between genetic and environmental factors. High-
income countries have faced an allergy epidemic during 
the past 3–4 decades, with nearly one in four children 
diagnosed with allergic rhinitis, asthma, or eczema. An 
increasing prevalence of allergic rhinitis and asthma has 
also been reported in the Indian subcontinent.1,2 India is 
the second most populous country (1·35 billion people) 
in the world and is classified as a lower-middle income 
country. Nearly 20% of the world’s population live in 
India.
An estimated 300 million people worldwide have 
asthma, with 37·9 million in India, equal to 55% of the 
total UK population.3 The burden of asthma in India 
exceeds the number of people with HIV infection or 
tuberculosis. The phase 3 International Study of Asthma 
and Allergy in Children (ISAAC)1 reported an overall 
prevalence of current wheeze of 7% in Indian children 
aged 6–7 years and aged 13–14 years, with a higher 
prevalence of up to 10–20% in some areas.2 Importantly, 
50% or more of this cohort had severe uncontrolled 
asthma.1 An Indian study reported that prevalence of 
allergic rhinitis was 11·3% in children aged 6–7 years, and 
24·4% in children aged 13–14 years.2 The ISAAC study4 
reported 2·7% overall prevalence of current eczema 
among Indian children aged 6–7 years, and 3·6% among 
Indian children aged 13–14 years. In contrast to the 
high prevalence of rhinitis, asthma, and eczema, food 
allergy was low at 0·14% among Indian children aged 
6–11 years.5
What are the implications of these data from a 
public and global health viewpoint? Inhaled and 
intranasal corticosteroids constitute the mainstay 
therapies in asthma and rhinitis. Allergic rhinitis co-
occurs in 60–70% of children with asthma, and optimal 
management of rhinitis has a positive effect on the 
long-term clinical management of asthma. However, 
inhaled and intranasal corticosteroids are unaffordable 
for patients with low incomes (India’s per capita gross 
domestic product is US$2172), who often resort to 
suboptimal oral medications. Patients from middle 
and low socioeconomic groups with severe asthma are 
also deprived of immunomodulatory biologic therapies 
such as omalizumab and mepolizumab because these 
drugs are unaffordable. Clinical management of these 
patients might be further compromised by knowledge 
gaps among practitioners, religious beliefs and myths 
among patients or parents, social stigma of a chronic 
ailment, and fear of inhalers being habit-forming 
medicines.3
Worldwide, India has one of the highest concen-
trations of air pollution caused by biomass, fossil fuels, 
and vehicular exhausts, and the use of mosquito coils 
and incense and dhoop sticks is an important cause of 
indoor pollution.6 Nearly 77% of the Indian population 
is exposed to PM2·5 exceeding the limit of 40 µg/m³ set 
by National Air Quality Standards in India (the limit set 
by WHO is <10 µg/m³).7 Exposure to ambient PM2·5 is 
associated with asthma exacerbations, cardiovascular 
events, and premature deaths, and is associated with 
26·2% of global disability adjusted life years.7,8
Within India, there are variations with respect to 
weather, pollens and fungal spores, insects such as 
cockroaches, and other living conditions, and meteoro-
logical data regarding environmental allergens are 
sparse.9 This variation in conditions and absence 
of data is further complicated by an absence of 
access to standardised allergen extracts for skin 
tests in India, making an accurate allergy diagnosis 
challenging, leading to poor characterisation of disease 
and generating unreliable epidemiological data.9 
Additionally, standardised allergen-specific immuno-
therapy (desensitisation treatment) extracts are not 
generally available in India, making management of 
moderate–severe allergic rhinitis challenging.
Patient-level risk stratification and characterisation 
of disease are key to planning therapeutic strategies.10 
Phenotypic clustering based on published evidence10 
generated from high-income countries might not be 
directly applicable to the Indian population because 
of environmental confounders, such as air pollution 
and parasitic infestation. Parasitic infestation is 
particularly relevant in the context of biomarkers such 
as peripheral blood eosinophils, serum total IgE, and 
sputum neutrophils and eosinophils. Environmental 
confounders are also relevant in the context of 
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patient selection for treatment with biologics such as 
omalizumab and mepolizumab.10
Provision of self-injectable epinephrine autoinjectors 
is essential to the long-term management of 
anaphylaxis because prompt treatment underpins 
a favourable clinical outcome. These autoinjectors 
are currently unavailable in India and patients carry 
predrawn epinephrine in a 1 ml tuberculin syringe for 
emergency use. This practice is clearly a clinical risk and 
does not satisfy basic principles of health and safety.
The field of allergy has not gained an independent 
specialty status in India, and training is sparse and 
embedded within respiratory medicine. Therefore, 
there is an urgent need for a strategic, multipronged, 
multiprofessional, concerted approach to tackle 
the burden of allergic diseases and improve air 
quality standards in the Indian subcontinent. 
Specific focus is needed on education and training 
for patients and health-care professionals in allergy, 
improving access to high-quality allergen extracts for 
immunodiagnostics, and on safe delivery of allergen-
specific immunotherapies. Phenotypic characterisation 
of allergic conditions in the Indian population will be 
crucial for the development of precision and personalised 
medicine for allergic diseases. Initiatives driven by 
the pharmaceutical industry and the involvement of 
relevant regulatory authorities are urgently needed for 
making self-injectable epinephrine autoinjectors and 
essential treatments for rhinitis and asthma accessible at 
subsidised and affordable prices.
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